CC Small or few human trials. Promising, not proven. How we grade →RCT (pilot) · 25 adults aged 70 to 95
A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
E Kraig, L Linehan, H Liang, T Romo, Q Liu, Y Wu et al. Experimental Gerontology. 2018.
- In plain language
- 1 mg of rapamycin a day for 8 weeks lowered several red blood cell measures without clinical effects; glucose tolerance, cognition and physical performance did not change.
- Limits
- Very small and short; 11 on rapamycin analyzed.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Rapamycin and mTOR: strong mouse lifespan data, early human trials
- Source
- doi.org/10.1016/j.exger.2017.12.026 · PubMed 29408453 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.